... Jubilant’s demonstrated and proprietary portfolio of drug development capabilities toward discoveries made by the faculty ... studies to be conducted in Kolkata, India. One will be the development of a cohort to gain insights into the clinical and molecular ... Dzau. “However, achievement of these goals necessitates the development of a continuum that spans discovery and translation sciences ...

... . For starters, PPD next year plans to spin off its drug-development division as a separate publicly traded company. ... in the contract research side. The new company will work with other drug companies on new medicines, including a treatment for premature ejaculation that ... sales have slowed as pharmaceutical customers scale back development of expensive new drugs. Third-quarter revenue fell about ...

A commentary published online 23 October in the Journal of the National Cancer Institute summarises a set of critical decision points in cancer biomarker and drug development. The points, which emerged from a workshop, include developing a clear understanding of the biology of the target and its interaction with the drug and the factors affecting the performance of the biomarker assay...

... Vivus and Arena Pharmaceuticals, each of which is at work on a new obesity drug. And New York Times scribe Andrew Pollack says ... mixes phentermine and topiramate, a generic epilepsy drug which has been known to leave patients befuddled. And some doctors, writes ... antidepressant bupropion. Only Arena's Lorcaserin is a new drug. But a history of serious side effects from earlier therapies is ...

... who work there. However, the thing that really caught my attention in this article is that the cost to develop a new drug has moved from US $800 Million to US $1.3-1.5 Billion in just a few years. I ... of its workforce in order to generate cost savings needed to finance increasingly costly drug research and to weather future challenges, the diversified healthcare company said on Tuesday. J&J ...

... life and improving tissue uptake. The Companys own research and development activities focus on infectious diseases and metabolic disorders ... genetic disorders and inflammatory diseases. The Companys own research and development activities focus on infectious diseases and metabolic disorders ... Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/ ...